FDC

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE258B01022
  • NSEID: FDC
  • BSEID: 531599
INR
414.05
-0.05 (-0.01%)
BSENSE

Dec 05

BSE+NSE Vol: 45.46 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

45.46 k (-66.99%) Volume

Shareholding (Sep 2025)

FII

2.43%

Held by 100 FIIs

DII

0.12%

Held by 9 DIIs

Promoter

69.66%

When is the next results date for FDC?

06-Jun-2025

No Upcoming Board Meetings

Who are in the management team of FDC?

06-Jun-2025

As of March 2022, the management team of FDC includes Mohan A Chandavarkar (Managing Director), Ashok A Chandavarkar (Director), Nandan M Chandavarkar (Joint Managing Director), Ameya A Chandavarkar (Executive Director & CEO), and several independent and non-executive directors, ensuring diverse governance and strategic direction.

As of March 2022, the management team of FDC includes:<BR><BR>1. Mohan A Chandavarkar - Managing Director<BR>2. Ashok A Chandavarkar - Director<BR>3. Nandan M Chandavarkar - Joint Managing Director<BR>4. Ameya A Chandavarkar - Executive Director & CEO<BR>5. Ramdas A Chandavarkar - Chairman Emeritus<BR>6. Varsharani Katre - Company Secretary & Compliance Officer<BR>7. Nomita R Chandavarkar - Director<BR>8. Swati S Mayekar - Independent Director<BR>9. Uday Kumar Gurkar - Chairman & Independent Director<BR>10. Melarkode Ganesan Parameswaran - Independent Director<BR>11. Usha Athreya Chandrasekhar - Independent Director<BR>12. Mahesh Bijlani - Independent Director<BR>13. Vijay Maniar - Additional Independent Director<BR><BR>This team comprises a mix of executive, independent, and non-executive directors, contributing to the governance and strategic direction of the company.

Read More

What does FDC do?

06-Jun-2025

FDC Ltd is a mid-cap, research-oriented pharmaceutical company in India that manufactures and markets formulations and active pharmaceutical ingredients. As of March 2025, it reported net sales of ₹492 Cr and a net profit of ₹39 Cr, with a market cap of ₹7,004 Cr.

Overview: <BR>FDC Ltd is a fully integrated, research-oriented pharmaceutical company engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients, operating within the Pharmaceuticals & Biotechnology industry as a mid-cap entity.<BR><BR>History: <BR>FDC Ltd was incorporated in an unspecified year and has maintained its status as a prominent player in the Indian pharmaceutical industry. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 492 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 39 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 7,004 Cr (Mid Cap) <BR><BR>Key Metrics: <BR>P/E: 26.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 1.15% <BR>Debt-Equity: -0.23 <BR>Return on Equity: 11.70% <BR>Price to Book: 3.10 <BR><BR>Contact Details: <BR>Address: B-8 MIDC Industrial Area, Waluj Dist Aurangabad (Maharashtra) Maharashtra : 431136 <BR>Phone: 91-240-2554407/967/299 <BR>Email: investors@fdcindia.com <BR>Website: http://www.fdcindia.com

Read More

Has FDC declared dividend?

06-Jun-2025

FDC Ltd has declared a 500% dividend, amounting to ₹5 per share, with an ex-date of November 22, 2024. While recent returns have shown volatility, the company has demonstrated positive growth over the longer term, particularly in the 2 to 5-year periods.

FDC Ltd has declared a 500% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 500%<BR>- Amount per share: 5 per share<BR>- Ex-date: 22 Nov 24<BR><BR>Dividend Yield: 1.15%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -16.29%, with a dividend return of 0%, resulting in a total return of -16.29%.<BR><BR>Over the past year, the price return was -1.42%, the dividend return was 1.11%, leading to a total return of -0.31%.<BR><BR>In the 2-year period, the price return was 45.65%, the dividend return was 1.62%, culminating in a total return of 47.27%.<BR><BR>For the 3-year period, the price return was 75.79%, the dividend return was 2.16%, resulting in a total return of 77.95%.<BR><BR>In the last 4 years, the price return was 27.43%, the dividend return was 1.40%, leading to a total return of 28.83%.<BR><BR>Over the past 5 years, the price return was 64.51%, the dividend return was 1.86%, culminating in a total return of 66.37%.<BR><BR>Overall, FDC Ltd has declared a significant dividend, and while recent returns show some volatility, the longer-term performance indicates positive growth, particularly over the 2 to 5-year periods.

Read More

Who are the peers of the FDC?

03-Jun-2025

FDC's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, SPARC, Supriya Lifesci, Innova Captab, Sequent Sciences, and Hikal. FDC has average management risk and below average growth compared to its peers, with a 1-year return of 1.55%.

Peers: The peers of FDC are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, SPARC, Supriya Lifesci., Innova Captab, Sequent Scien., and Hikal.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Supriya Lifesci., while Good management risk is found at Divi's Lab., Torrent Pharma, and Innova Captab. Average management risk is present at FDC, Sequent Scien., and Hikal, while Below Average management risk is noted for SPARC. Growth is Excellent for Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Innova Captab, while Below Average growth is seen at Divi's Lab., Torrent Pharma, FDC, SPARC, Supriya Lifesci., and Hikal. The rest have Good growth. Excellent capital structure is noted for Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, FDC, Supriya Lifesci., and Innova Captab, while Good capital structure is found at Torrent Pharma, Average at Hikal, and Below Average at SPARC and Sequent Scien.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Supriya Lifesci. at 101.03%, while the lowest is SPARC at -7.92%. FDC's own 1-year return is 1.55%, which is significantly lower than the highest and higher than the lowest. Additionally, the peers with negative six-month returns include FDC, SPARC, and Hikal.

Read More

Is FDC overvalued or undervalued?

09-Jun-2025

As of March 5, 2025, FDC is considered overvalued with a valuation grade of expensive, reflected by a PE ratio of 26.12 and a year-to-date return of -12.40%, compared to the Sensex's 5.59%.

As of 5 March 2025, the valuation grade for FDC has moved from fair to expensive, indicating that the company is currently overvalued. The key ratios supporting this assessment include a PE ratio of 26.12, an EV to EBITDA of 20.33, and a Price to Book Value of 3.05. Compared to its peers, FDC's valuation appears high; for instance, Sun Pharma has a PE ratio of 35.25, while Cipla, considered attractive, has a PE of 22.99.<BR><BR>In light of these metrics, FDC is deemed overvalued relative to its industry peers. The company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -12.40% compared to the Sensex's 5.59%, further reinforcing the notion that the stock may not be a favorable investment at its current price of 434.75.

Read More

Who are the top shareholders of the FDC?

17-Jul-2025

The top shareholders of FDC include promoter Nomita R Chandavarkar with 22.67%, mutual funds at 6.18%, foreign institutional investors at 2.55%, and individual investors collectively owning 16.22%. The largest public shareholder is the ICICI Prudential Smallcap Fund, holding 2.87%.

The top shareholders of FDC include the promoters, who hold the majority of the shares. The promoter with the highest holding is Nomita R Chandavarkar, owning 22.67% of the company. In addition, mutual funds hold 6.18% of the shares through 10 different schemes, while foreign institutional investors (FIIs) hold 2.55% through 105 different entities. The highest public shareholder is the ICICI Prudential Smallcap Fund, which holds 2.87%. Individual investors collectively own 16.22% of the company.

Read More

How big is FDC?

24-Jul-2025

As of 24th July, FDC Ltd has a market capitalization of 7,983.00 Cr, with recent net sales of 2,108.12 Cr and net profit of 266.79 Cr over the last four quarters.

As of 24th July, <BR><BR>Market Cap: FDC Ltd has a market capitalization of 7,983.00 Cr and is classified as a Mid Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 2,108.12 Cr, while the sum of Net Profit for the same period is 266.79 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2024, with Shareholder's Funds amounting to 2,097.17 Cr and Total Assets valued at 2,468.09 Cr.

Read More

Are FDC latest results good or bad?

06-Nov-2025

FDC's latest Q2 FY26 results are concerning, with net profit down 76.62% QoQ to ₹28.37 crores and revenue decreasing by 27.05% QoQ to ₹473.03 crores, indicating significant operational challenges and margin pressure. Year-on-year comparisons also show declines, raising concerns about the company's performance.

FDC's latest results for Q2 FY26 are concerning and can be classified as bad. The company reported a significant decline in both net profit and revenue. Specifically, net profit fell by 76.62% quarter-on-quarter (QoQ) to ₹28.37 crores, and revenue decreased by 27.05% QoQ to ₹473.03 crores. <BR><BR>Additionally, the operating margin, excluding other income, collapsed to 7.15% from 21.65% in the previous quarter, marking the lowest level in recent history. This sharp decline in profitability raises serious concerns about the company's operational efficiency and competitive positioning in the market.<BR><BR>The year-on-year (YoY) comparisons also reflect a negative trend, with net profit down 60.62% and revenue down 7.94%. The reliance on non-operating income, which constituted a significant portion of profit before tax, further highlights the challenges faced by FDC's core operations.<BR><BR>Overall, the results indicate acute operational challenges and significant margin pressure, suggesting that the company is currently struggling to maintain its performance.

Read More

Should I buy, sell or hold FDC?

06-Nov-2025

How has been the historical performance of FDC?

06-Nov-2025

FDC has shown consistent growth in net sales, increasing from 1,090.70 Cr in Mar'19 to 2,108.12 Cr in Mar'25, while total assets rose to 2,713.80 Cr. However, profit margins and earnings per share have experienced volatility, with EPS declining from 18.75 in Mar'24 to 16.39 in Mar'25.

Answer:<BR>The historical performance of FDC shows a consistent growth trend in net sales and overall financial metrics over the years.<BR><BR>Breakdown:<BR>FDC's net sales have increased from 1,090.70 Cr in Mar'19 to 2,108.12 Cr in Mar'25, reflecting a steady growth trajectory. The total operating income has similarly risen, reaching 2,108.12 Cr in Mar'25 from 1,090.70 Cr in Mar'19. However, the total expenditure has also grown, amounting to 1,783.32 Cr in Mar'25, up from 859.68 Cr in Mar'19. Operating profit (PBDIT) has fluctuated, peaking at 440.17 Cr in Mar'24 before dropping to 415.46 Cr in Mar'25. Profit before tax reached 357.22 Cr in Mar'25, while profit after tax was recorded at 266.79 Cr. The earnings per share (EPS) decreased from 18.75 in Mar'24 to 16.39 in Mar'25, indicating a decline despite the growth in sales. On the balance sheet, total assets increased from 1,812.93 Cr in Mar'20 to 2,713.80 Cr in Mar'25, with total liabilities also rising to 2,713.80 Cr in Mar'25. Cash flow from operating activities improved significantly to 317.00 Cr in Mar'25 from 220.00 Cr in Mar'24, contributing to a net cash inflow of 26.00 Cr in Mar'25. Overall, FDC has demonstrated growth in sales and assets, although profit margins and EPS have shown some volatility.

Read More

Is FDC technically bullish or bearish?

19-Nov-2025

As of November 18, 2025, FDC's technical trend has shifted to a moderate bearish stance, driven by bearish MACD, moving averages, and Bollinger Bands, despite a conflicting bullish signal from the OBV on the monthly timeframe.

As of 18 November 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance for FDC is bearish with a moderate strength. Key indicators driving this stance include a bearish MACD on the weekly timeframe, bearish moving averages on the daily timeframe, and a bearish signal from Bollinger Bands on both weekly and monthly timeframes. The KST is also bearish on the weekly, reinforcing the negative outlook. Although the OBV shows a bullish signal on the monthly, it does not outweigh the overall bearish indicators.

Read More

Why is FDC falling/rising?

05-Dec-2025

As of 05-Dec, FDC Ltd's stock price is rising to 416.30, supported by recent gains, increased investor participation, and sector outperformance. Despite longer-term declines, the stock shows a positive short-term trend, trading above its 5-day and 20-day moving averages.

As of 05-Dec, FDC Ltd's stock price is rising, currently at 416.30, reflecting an increase of 2.45 (0.59%). This upward movement is supported by several factors. The stock has outperformed its sector by 0.8% today and has experienced consecutive gains over the last two days, with a total return of 0.63% during this period. Additionally, there has been a significant increase in investor participation, with delivery volume on December 4 rising by 486.83% compared to the 5-day average. <BR><BR>While the stock has shown a decline over longer periods, such as a 6.98% drop over the past month and a 16.12% decline year-to-date, the current performance indicates a positive short-term trend. The stock is trading higher than its 5-day and 20-day moving averages, although it remains below the longer-term moving averages of 50, 100, and 200 days. This suggests that while the stock is experiencing a rise in the short term, it may still be recovering from previous declines. Overall, the combination of recent gains, increased trading activity, and sector outperformance contributes to the current rise in FDC Ltd's stock price.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Poor long term growth as Operating profit has grown by an annual rate -5.46% of over the last 5 years

  • PAT(Q) At Rs 28.37 cr has Fallen at -57.8% (vs previous 4Q average)
  • NET SALES(Q) At Rs 473.03 cr has Fallen at -10.7% (vs previous 4Q average)
  • DEBTORS TURNOVER RATIO(HY) Lowest at 1.26 times
2

With ROE of 9.3, it has a Expensive valuation with a 2.8 Price to Book Value

3

Below par performance in long term as well as near term

stock-summaryMojo Parameters
Mojo Parameters
Loading Valuation Snapshot...
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

INR 6,705 Cr (Small Cap)

stock-summary
P/E

30.00

stock-summary
Industry P/E

34

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.17

stock-summary
Return on Equity

9.27%

stock-summary
Price to Book

2.78

Revenue and Profits:
Net Sales:
473 Cr
(Quarterly Results - Sep 2025)
Net Profit:
28 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-12.08%
0%
-12.08%
6 Months
-4.75%
0%
-4.75%
1 Year
-20.04%
0%
-20.04%
2 Years
2.58%
1.27%
3.85%
3 Years
45.08%
1.81%
46.89%
4 Years
45.54%
1.72%
47.26%
5 Years
20.03%
1.50%
21.53%

Latest dividend: 5 per share ex-dividend date: Nov-22-2024

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions
News
Announcements stock-summary

FDC Limited - Clarification - Financial Results

14-Nov-2019 | Source : NSE

FDC Limited for the quarter ended 30-Sep-2019 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

FDC Limited - Updates

18-Oct-2019 | Source : NSE

FDC Limited has informed the Exchange regarding 'Acquisition of Registered Trademark/ Brand "ENTEROPLUS" from GlaxoSmithKline Pharmaceuticals Limited (GSK)'.

FDC Limited - Updates

16-Oct-2019 | Source : NSE

FDC Limited has informed the Exchange regarding 'Certificate in terms of Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 ( said regulations ) on behalf of FDC Limited ( the Company ) for the quarter ended on September 30, 2019'.'.

Corporate Actions stock-summary
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

FDC Ltd has declared 500% dividend, ex-date: 22 Nov 24

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
9.26%
EBIT Growth (5y)
-5.46%
EBIT to Interest (avg)
62.47
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.17
Sales to Capital Employed (avg)
0.85
Tax Ratio
25.44%
Dividend Payout Ratio
30.51%
Pledged Shares
0
Institutional Holding
9.25%
ROCE (avg)
17.80%
ROE (avg)
11.97%
Valuation key factors
Factor
Value
P/E Ratio
30
Industry P/E
34
Price to Book Value
2.79
EV to EBIT
29.54
EV to EBITDA
23.19
EV to Capital Employed
3.14
EV to Sales
3.07
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
10.64%
ROE (Latest)
9.27%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 9 Schemes (6.63%)

FIIs

Held by 100 FIIs (2.43%)

Promoter with highest holding

Nomita R Chandavarkar (22.67%)

Highest Public shareholder

Icici Prudential Smallcap Fund (3.59%)

Individual Investors Holdings

16.4%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is -27.05% vs 31.82% in Jun 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is -76.62% vs 213.81% in Jun 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "473.03",
          "val2": "648.41",
          "chgp": "-27.05%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "33.82",
          "val2": "140.35",
          "chgp": "-75.90%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.15",
          "val2": "1.17",
          "chgp": "-1.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "28.37",
          "val2": "121.35",
          "chgp": "-76.62%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "7.15%",
          "val2": "21.65%",
          "chgp": "-14.50%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Consolidated) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2025 is -2.66% vs 12.65% in Sep 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": " Growth in half year ended Sep 2025 is -21.65% vs 6.33% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,121.44",
          "val2": "1,152.12",
          "chgp": "-2.66%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "175.59",
          "val2": "216.79",
          "chgp": "-19.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "2.32",
          "val2": "2.37",
          "chgp": "-2.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "149.72",
          "val2": "191.08",
          "chgp": "-21.65%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "15.66%",
          "val2": "18.82%",
          "chgp": "-3.16%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2024 is 9.14% vs 9.78% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2024 is -11.90% vs 58.54% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,616.23",
          "val2": "1,480.91",
          "chgp": "9.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "263.44",
          "val2": "282.21",
          "chgp": "-6.65%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "3.32",
          "val2": "3.08",
          "chgp": "7.79%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "228.12",
          "val2": "258.94",
          "chgp": "-11.90%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "16.30%",
          "val2": "19.06%",
          "chgp": "-2.76%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 8.50% vs 8.92% in Mar 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is -12.59% vs 57.30% in Mar 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,108.12",
          "val2": "1,942.94",
          "chgp": "8.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "324.80",
          "val2": "338.54",
          "chgp": "-4.06%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "4.51",
          "val2": "4.03",
          "chgp": "11.91%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "266.79",
          "val2": "305.22",
          "chgp": "-12.59%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "15.41%",
          "val2": "17.42%",
          "chgp": "-2.01%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQstock-summary
Sep'25
Jun'25
Change(%)
Net Sales
473.03
648.41
-27.05%
Operating Profit (PBDIT) excl Other Income
33.82
140.35
-75.90%
Interest
1.15
1.17
-1.71%
Exceptional Items
0.00
0.00
Consolidate Net Profit
28.37
121.35
-76.62%
Operating Profit Margin (Excl OI)
7.15%
21.65%
-14.50%
Values in Rs Cr.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Sep 2025 is -27.05% vs 31.82% in Jun 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Sep 2025 is -76.62% vs 213.81% in Jun 2025

Half Yearly Results Snapshot (Consolidated) - Sep'25stock-summary
Sep'25
Sep'24
Change(%)
Net Sales
1,121.44
1,152.12
-2.66%
Operating Profit (PBDIT) excl Other Income
175.59
216.79
-19.00%
Interest
2.32
2.37
-2.11%
Exceptional Items
0.00
0.00
Consolidate Net Profit
149.72
191.08
-21.65%
Operating Profit Margin (Excl OI)
15.66%
18.82%
-3.16%
Values in Rs Cr.
Direction Arrows
Net Sales

Growth in half year ended Sep 2025 is -2.66% vs 12.65% in Sep 2024

Direction Arrows
Consolidated Net Profit

Growth in half year ended Sep 2025 is -21.65% vs 6.33% in Sep 2024

Nine Monthly Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
1,616.23
1,480.91
9.14%
Operating Profit (PBDIT) excl Other Income
263.44
282.21
-6.65%
Interest
3.32
3.08
7.79%
Exceptional Items
0.00
0.00
Consolidate Net Profit
228.12
258.94
-11.90%
Operating Profit Margin (Excl OI)
16.30%
19.06%
-2.76%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in nine months ended Dec 2024 is 9.14% vs 9.78% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in nine months ended Dec 2024 is -11.90% vs 58.54% in Dec 2023

Annual Results Snapshot (Consolidated) - Mar'25stock-summary
Mar'25
Mar'24
Change(%)
Net Sales
2,108.12
1,942.94
8.50%
Operating Profit (PBDIT) excl Other Income
324.80
338.54
-4.06%
Interest
4.51
4.03
11.91%
Exceptional Items
0.00
0.00
Consolidate Net Profit
266.79
305.22
-12.59%
Operating Profit Margin (Excl OI)
15.41%
17.42%
-2.01%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is 8.50% vs 8.92% in Mar 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2025 is -12.59% vs 57.30% in Mar 2024

stock-summaryCompany CV
About FDC Ltd stock-summary
stock-summary
FDC Ltd
Small Cap
Pharmaceuticals & Biotechnology
FDC Limited is a fully integrated, research-oriented pharmaceutical company engaged in the manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs). The Company is a prominent player in the Indian pharmaceutical industry, renowned for its expertise in developing specialised formulations. It leads the market in sectors such as Oral Rehydration Solutions (ORS), energy drinks, antibiotics and ophthalmic therapies.
Company Coordinates stock-summary
Company Details
B-8 MIDC Industrial Area, Waluj Dist Aurangabad (Maharashtra) Maharashtra : 431136
stock-summary
Tel: 91-240-2554407/967/299
stock-summary
investors@fdcindia.com
Registrar Details
Sharex Dynamic (India) Pvt Ltd , Unit -1, Luthra Ind. Premises , Safed Pool, Andheri-Kurla Road, Andheri (E), Mumbai